Results of another phase 2b study – called SYMMETRY – showed that efruxifermin was unable to hit its main objective as a treatment for patients with compensated cirrhosis (F4) due to NASH ...

The HARMONY study compared two doses of Akero's FGF21 mimic efruxifermin to placebo over 24 weeks in 128 adult patients with biopsy-confirmed NASH, a serious form of non-alcoholic fatty liver ...

The adjustment follows Akero's presentation of promising 96-week SYMMETRY data for efruxifermin (EFX) in patients with compensated cirrhosis caused by metabolic-associated steatohepatitis (MASH F4C).

Shares of 89bio (NASDAQ:ETNB) were up 40% Monday afternoon, stoked by positive data for Akero Therapeutics' (NASDAQ:AKRO) drug efruxifermin in the treatment of compensated liver cirrhosis due to MASH.